Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Nuveen Asset Management LLC reduced its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 69.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 79,485 shares of the company's stock after selling 181,863 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.20% of Keros Therapeutics worth $1,258,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. MetLife Investment Management LLC increased its position in Keros Therapeutics by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock worth $286,000 after buying an additional 1,027 shares during the last quarter. Handelsbanken Fonder AB increased its position in Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after buying an additional 1,100 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Keros Therapeutics by 7.8% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company's stock worth $303,000 after buying an additional 1,386 shares during the last quarter. Virtus ETF Advisers LLC increased its position in Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after buying an additional 1,998 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Keros Therapeutics by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock worth $1,549,000 after buying an additional 2,462 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 20.60% of the stock is owned by company insiders.

Keros Therapeutics Trading Down 0.5%

Shares of NASDAQ KROS traded down $0.07 during mid-day trading on Friday, hitting $15.04. The company had a trading volume of 739,298 shares, compared to its average volume of 854,380. The company has a market capitalization of $610.85 million, a price-to-earnings ratio of -2.89 and a beta of 1.31. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The stock's 50-day moving average price is $13.44 and its 200-day moving average price is $17.76.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. During the same period in the previous year, the business earned ($1.21) earnings per share. As a group, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. HC Wainwright decreased their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Truist Financial decreased their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Wells Fargo & Company decreased their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Scotiabank decreased their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Finally, Wedbush reiterated a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research report on Friday, May 30th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.